Literature DB >> 19330107

Risk-assessment implications of mechanistic model's prediction of low-dose nonlinearity of liver tumor risk for mice fed fumonisin b(1).

Ralph L Kodell1, Angelo Turturro.   

Abstract

A two-stage, clonal-expansion model of liver tumor risk in mice was developed by Kodell et al. (Food Addit Contam 18:237-253, 2001) based on the hypothesis that fumonisin B(1), a naturally occurring mycotoxin in corn, is not genotoxic, but rather causes cancer through the disruption of sphingolipid metabolism. This disruption is assumed to cause an increase in apoptosis, in response to which cells proliferate to compensate for reduced tissue mass. The resulting differential increase in the number of pre-neoplastic cells at risk of mutation during cell division is assumed to lead to an increase in the incidence of tumors. Two-year liver tumor incidences predicted by the model using data on organ weight, cell proliferation, and sphingolipid metabolism provided a reasonable match to the actual 2-year observed incidences in a study conducted at the National Center for Toxicological Research. The predictions indicated no risk at low doses (even a possible hormetic effect) and high risk at high doses in females, as well as a complete absence of a dose response (or perhaps, a hormetic effect) in males. This paper provides a commentary on the risk-assessment implications of the modeling results, pointing out that the model's low-dose predictions provide scientific support and justification for the U.S. Food and Drug Administration's low-ppm guidance levels in corn products. These guidance levels are significantly higher than would be obtained using linear extrapolation, the method most often used for genotoxic carcinogens and other carcinogens for which low-dose linearity cannot be ruled out.

Entities:  

Keywords:  FDA guidance; apoptosis; hormesis; mycotoxin; nongenotoxic

Year:  2004        PMID: 19330107      PMCID: PMC2647820          DOI: 10.1080/15401420490426981

Source DB:  PubMed          Journal:  Nonlinearity Biol Toxicol Med        ISSN: 1540-1421


  11 in total

1.  Tissue sphinganine as a biomarker of fumonisin-induced apoptosis.

Authors:  R R Delongchamp; J F Young
Journal:  Food Addit Contam       Date:  2001-03

2.  Elevated sphingoid bases and complex sphingolipid depletion as contributing factors in fumonisin-induced cytotoxicity.

Authors:  H S Yoo; W P Norred; J Showker; R T Riley
Journal:  Toxicol Appl Pharmacol       Date:  1996-06       Impact factor: 4.219

3.  Leukoencephalomalacia in two horses induced by oral dosing of fumonisin B1.

Authors:  T S Kellerman; W F Marasas; P G Thiel; W C Gelderblom; M Cawood; J A Coetzer
Journal:  Onderstepoort J Vet Res       Date:  1990-12       Impact factor: 1.792

4.  Pi-class glutathione-S-transferase-positive hepatocytes in aging B6C3F1 mice undergo apoptosis induced by dietary restriction.

Authors:  L Muskhelishvili; A Turturro; R W Hart; S J James
Journal:  Am J Pathol       Date:  1996-11       Impact factor: 4.307

5.  A mechanistic approach to modelling the risk of liver tumours in mice exposed to fumonisin B1 in the diet.

Authors:  R L Kodell; J F Young; R R Delongchamp; A Turturro; J J Chen; D W Gaylor; P C Howard; Q Zheng
Journal:  Food Addit Contam       Date:  2001-03

6.  Toxicology and carcinogenesis studies of fumonisin B1 (cas no. 116355-83-0) in F344/N rats and B6C3F1 mice (feed studies).

Authors: 
Journal:  Natl Toxicol Program Tech Rep Ser       Date:  2001-12

7.  The cancer-initiating potential of the fumonisin B mycotoxins.

Authors:  W C Gelderblom; E Semple; W F Marasas; E Farber
Journal:  Carcinogenesis       Date:  1992-03       Impact factor: 4.944

Review 8.  Fumonisins, mycotoxins of increasing importance: their nature and their effects.

Authors:  M F Dutton
Journal:  Pharmacol Ther       Date:  1996       Impact factor: 12.310

9.  Characterization of fumonisin toxicity in orally and intravenously dosed swine.

Authors:  W M Haschek; G Motelin; D K Ness; K S Harlin; W F Hall; R F Vesonder; R E Peterson; V R Beasley
Journal:  Mycopathologia       Date:  1992-02       Impact factor: 2.574

10.  Apoptotic and anti-proliferative effects of fumonisin B1 in human keratinocytes, fibroblasts, esophageal epithelial cells and hepatoma cells.

Authors:  W H Tolleson; W B Melchior; S M Morris; L J McGarrity; O E Domon; L Muskhelishvili; S J James; P C Howard
Journal:  Carcinogenesis       Date:  1996-02       Impact factor: 4.944

View more
  1 in total

1.  General Principles for the Validation of Proarrhythmia Risk Prediction Models: An Extension of the CiPA In Silico Strategy.

Authors:  Zhihua Li; Gary R Mirams; Takashi Yoshinaga; Bradley J Ridder; Xiaomei Han; Janell E Chen; Norman L Stockbridge; Todd A Wisialowski; Bruce Damiano; Stefano Severi; Pierre Morissette; Peter R Kowey; Mark Holbrook; Godfrey Smith; Randall L Rasmusson; Michael Liu; Zhen Song; Zhilin Qu; Derek J Leishman; Jill Steidl-Nichols; Blanca Rodriguez; Alfonso Bueno-Orovio; Xin Zhou; Elisa Passini; Andrew G Edwards; Stefano Morotti; Haibo Ni; Eleonora Grandi; Colleen E Clancy; Jamie Vandenberg; Adam Hill; Mikiko Nakamura; Thomas Singer; Liudmila Polonchuk; Andrea Greiter-Wilke; Ken Wang; Stephane Nave; Aaron Fullerton; Eric A Sobie; Michelangelo Paci; Flora Musuamba Tshinanu; David G Strauss
Journal:  Clin Pharmacol Ther       Date:  2019-11-10       Impact factor: 6.903

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.